Skip to content
OpenCapital
Get started

Precigen PGEN Research and development commitments not yet incurred

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×—

Profitability

See full
Gross margin83.6%—
Operating margin-2,890.9%—
Net margin-3,656%—
FCF margin-1,756.5%—

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×—
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's research and development commitments not yet incurred.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's research and development commitments not yet incurred?
Precigen (PGEN) reported research and development commitments not yet incurred of $5.04M in Q1 2026.
How has Precigen's research and development commitments not yet incurred changed year-over-year?
Precigen's research and development commitments not yet incurred increased by 2.6% year-over-year, from $4.91M to $5.04M.
What is the long-term trend for Precigen's research and development commitments not yet incurred?
Over 3 years (2022 to 2025), Precigen's research and development commitments not yet incurred has grown at a -32.1% compound annual growth rate (CAGR), from $19.91M to $6.22M.